

Filed: June 7, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner

v.

BIOGEN MA INC.

Patent Owner

Case No. IPR2018-01403
U.S. Patent No. 8,399,514

PETITIONER'S OBJECTIONS TO PATENT OWNER'S EVIDENCE

Pursuant to 37 C.F.R. § 42.64(b)(1), Petitioner Mylan Pharmaceuticals Inc. (“Petitioner”) objects to the admissibility of the following exhibits filed by Patent Owner Biogen MA Inc. (“Biogen” or “Patent Owner”) in the Patent Owner’s Response in the above-captioned *inter partes* review.

Petitioner’s objections are timely under 37 C.F.R. § 42.64(b)(1) because they are being filed and served within five business days. Petitioner’s objections provide notice to Biogen that Petitioner may move to exclude these exhibits under 37 C.F.R. § 42.64(c).

In this paper, a reference to “FRE” means the Federal Rules of Evidence, a reference to “CFR” means the Code of Federal Regulations, and “’514 patent” means U.S. Patent No. 8,399,514. All objections under FRE 801-803 (hearsay) apply to the extent Patent Owner relies on the exhibits identified in connection with that objection for the truth of the matter asserted therein.

Exhibit descriptions provided in this table are from Patent Owner’s exhibit list and are used for identification purposes only. The use of the description does not indicate that Petitioner agrees with the descriptions or characterizations of the documents.

Exhibit	Description	Objection
BGN 2001	Chapters 1 and 4 from Alastair Compston et al., <i>MCALPINE'S MULTIPLE SCLEROSIS</i> (4th ed. 2006)	A, B, C, K, M, N, O
BGN 2002	European Medicines Agency, Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis, Doc Ref. CPMP/EWP/561/98 Rev. 1 (Nov. 16, 2006), <i>available at</i> https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-product-treatment-multiple-sclerosis_en.pdf (last accessed Nov. 1, 2018)	A, B, C, D, F, M, N, O
BGN 2003	FDA Clinical Review for NDA 204063 by Heather Fitter, M.D. (Review Completion Date: 11/08/2012)	A, B, C, D, E, F, I, K, L, M, N, O, U
BGN 2004	Australian Government, Department of Health, Therapeutic Goods Administration, Australian Public Assessment Report for Dimethyl Fumarate, Proprietary Product Name: Tecfidera (October 2013), <i>available at</i> https://www.tga.gov.au/sites/default/files/auspar-dimethyl-fumarate-131022.pdf (last accessed Nov. 1, 2018)	A, B, C, D, E, F, I, K, L, M, N, O, U
BGN 2005	Press Release, Biogen, <i>TECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis</i> (Feb. 3, 2014) (published by BUSINESS WIRE)	A, B, C, D, E, F, I, K, M, N, O
BGN 2006	Douglas Quenqua, Existential Animal News and the World's Lightest Solid, N.Y. TIMES, April 2, 2013, <i>available at</i> http://www.nytimes.com/2013/04/02/science/existential-animal-news-and-the-worlds-lightest-solid.html?_r=0 (last accessed Nov. 1, 2018)	A, B, C, D, E, F, I, K, L, M, N, O

Exhibit	Description	Objection
BGN 2007	Bill Berkrot, <i>Biogen Profit Beats Estimates, Raises 2013 Forecast</i> , REUTERS (Apr. 25, 2013), http://www.reuters.com/article/usbiogenidec-results-idUSBRE93O0Q920130425 (last accessed Nov. 1, 2018)	A, B, C, D, E, F, I, K, M, N, O
BGN 2008	<i>ViewPoints: Biogen Idac Struggling to Cope with Tecfidera Demand Suggests Analyst</i> , FIRSTWORD PHARMA (June 12, 2013), https://www.firstwordpharma.com/node/1105932?tsid=17 (last accessed Nov. 1, 2018)	A, B, C, D, E, F, I, K, M, N, O
BGN 2009	News Release, Biogen, <i>Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care</i> (Oct. 4, 2018) (published by ENP Newswire)	A, B, C, D, E, F, I, K, M, N, O
BGN 2010	News Release, Biogen, <i>Biogen Reports Quarterly Revenues of \$3.1 Billion</i> (Apr. 24, 2018) (published by BUSINESS WIRE), available at https://www.businesswire.com/news/home/20180424005550/en/ (last accessed Nov. 7, 2018)	A, B, C, D, E, F, I, K, L, M, N, O, T
BGN 2011	<i>RESERVED</i>	P
BGN 2012	<i>RESERVED</i>	P
BGN 2013	Defendant Mylan Pharmaceuticals Inc.'s Answer, Separate Defenses and Counterclaims to Complaint, <i>Biogen Int'l GmbH & Biogen MA Inc. v. Mylan Pharm. Inc.</i> , No. 1:17-cv-116, Dkt. 25 (N.D.W. Va. Aug. 7, 2017)	C, E, M, N, O, V
BGN 2014	Scheduling Order, <i>Biogen Int'l GmbH & Biogen MA Inc. v. Mylan Pharm. Inc.</i> , No. 1:17-cv-116, Dkt. 56 (N.D.W. Va. Nov. 6, 2017)	C, E, M, N, O, V
BGN 2015	Preliminary Amendment and Declaration of Katherine T. Dawson, M.D. Under 37 C.F.R. § 1.132 in U.S. Appl. No. 13/372,426 (Feb. 14, 2012) (cover page from <i>Coalition II</i>)	A, B, C, D, E, F, G, H, I, K, L, M, N, O, Q, R, S, T, U, W, X

Exhibit	Description	Objection
BGN 2016	Information Disclosure Statement in U.S. Appl. No. 13/372,426 (Feb. 13, 2012)	A, B, C, E, I, K, L, M, N, O, W, X
BGN 2017	First Supplemental Information Disclosure Statement in U.S. Appl. No. 13/372,426 (Feb. 13, 2012)	A, B, C, E, I, K, L, M, N, O, W, X
BGN 2018	Non-Final Office Action in U.S. Appl. No. 13/372,426 (May 3, 2012)	A, B, C, D, E, F, I, K, L, M, N, O, W, X
BGN 2019	Amendment and Reply Under 37 C.F.R. § 1.111 in U.S. Appl. No. 13/372,426 (August 3, 2012)	A, B, C, D, E, F, I, K, L, M, N, O, Q, S, T, U, W, X
BGN 2020	Declaration of Richard A. Rudick, M.D. Under 37 C.F.R. § 1.132, submitted with Response to Non-Final Office Action in U.S. Appl. No. 13/372,426 (August 3, 2012)	A, B, C, D, E, F, G, H, I, K, L, M, N, O, Q, S, T, U, W, X
BGN 2021	Final Office Action in U.S. Appl. No. 13/372,426 (October 12, 2012)	A, B, C, D, E, F, I, K, L, M, N, O, W, X
BGN 2022	Reply to Final Office Action Under 37 C.F.R. § 1.116 in U.S. Appl. No. 13/372,426 (December 12, 2012)	A, B, C, D, E, F, I, K, L, M, N, O, W, X
BGN 2023	Notice of Allowance in U.S. Appl. No. 13/372,426 (December 26, 2012)	A, B, C, D, E, F, I, K, L, M, N, O, W, X
BGN 2024	First Amended Petition (Paper 9) in <i>Coalition for Affordable Drugs V LLC v. Biogen MA Inc.</i> , IPR2015-01136 (“ <i>Coalition I</i> ”) (May 27, 2015)	A, C, E, I, M, N, O, Q, S, U, W, X
BGN 2025	Petitioner’s Exhibit List (Paper 10) in <i>Coalition for Affordable Drugs V LLC v. Biogen MA Inc.</i> , IPR2015-01136 (“ <i>Coalition I</i> ”) (May 27, 2015)	A, C, E, I, K, M, N, O, W, X

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.